| Proposed mechanisms for association between ABO blood type and SARS‐CoV‐2 infection |
| Anti‐A and/or anti‐B antibodies serve as viral neutralizing antibodies by binding to A and/or B antigens expressed on the viral envelope, thereby preventing infection of target cells |
| The SARS‐CoV‐2 S protein is bound by human anti‐A antibodies, which may block the interaction between the virus and ACE2R, thereby preventing entry into the lung epithelium |
| An increase in ACE‐1 activity in group A individuals predisposes to cardiovascular complications, accounting for severe COVID‐19 |
| Variation of VWF and Factor VIII levels by ABO type with higher levels in group A individuals contributing to risk of thromboembolic disease and severe COVID‐19 |
| ABH glycans, if present on SARS‐CoV‐2 S protein, may modify the affinity of SARS‐CoV‐2 for ACE2R, its cellular receptor. |
| ABH glycans on target cells could serve as alternative, lower‐affinity receptors for SARS‐CoV‐2 S protein or bind other viral envelope structures. |
| Suggested experiments to confirm the proposed associations between ABO blood groups and SARS‐CoV‐2 infection |
| In vitro production of recombinant SARS‐CoV‐2 S protein in cell lines that can synthesize ABH glycans to determine whether these are, indeed, on the recombinant protein. |
| Culturing SARS‐CoV‐2 in cell lines capable of synthesizing ABH glycans, isolating the virus and determining whether anti‐A and anti‐B prevent infection of cell lines that do not express the corresponding ABH antigen. These experiments would also allow testing whether IgM and IgG anti‐A (or anti‐B) antibodies were equally effective. |
| Producing recombinant SARS‐CoV‐2 S protein in identical host cell lines (e.g. by transfecting in the relevant glycosyltransferases) and then quantifying the affinity of the purified proteins for their receptor. This can determine if ABH glycans are present on SARS‐CoV‐2 S protein and if they modify the affinity of SARS‐CoV‐2 for ACE2R. |
| Produce SARS‐CoV‐2 in vitro in ABH‐expressing cell lines; and quantify the infectivity of a given target cell line with purified virus. |
| Quantify IgA anti‐A and/or anti‐B and correlate with risk of susceptibility to infection by SARS‐CoV‐2 and severity COVID‐19 illness. |
Source:
ABO blood group and COVID‐19: a review on behalf of the ISBT COVID‐19 working group
See also:
English
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Basque
Belarusian
Bengali
Bosnian
Bulgarian
Catalan
Cebuano
Chichewa
Chinese (Simplified)
Chinese (Traditional)
Corsican
Croatian
Czech
Danish
Dutch
Esperanto
Estonian
Filipino
Finnish
French
Frisian
Galician
Georgian
German
Greek
Gujarati
Haitian Creole
Hausa
Hawaiian
Hebrew
Hindi
Hmong
Hungarian
Icelandic
Igbo
Indonesian
Irish
Italian
Japanese
Javanese
Kannada
Kazakh
Khmer
Korean
Kurdish (Kurmanji)
Kyrgyz
Lao
Latin
Latvian
Lithuanian
Luxembourgish
Macedonian
Malagasy
Malay
Malayalam
Maltese
Maori
Marathi
Mongolian
Myanmar (Burmese)
Nepali
Norwegian
Pashto
Persian
Polish
Portuguese
Punjabi
Romanian
Russian
Samoan
Scottish Gaelic
Serbian
Sesotho
Shona
Sindhi
Sinhala
Slovak
Slovenian
Somali
Spanish
Sudanese
Swahili
Swedish
Tajik
Tamil
Telugu
Thai
Turkish
Ukrainian
Urdu
Uzbek
Vietnamese
Welsh
Xhosa
Yiddish
Yoruba
Zulu
There are some post Mendelian genetics at work her. For a short summary see
https://torontosun.com/news/world/neanderthal-gene-protects-against-covid-19 and the specific article at https://www.medrxiv.org/content/10.1101/2020.10.13.20212092v4.full-text.
My Rh neg intuition makes note of the back migrations of OAS1 and admixture between sub-Saharans, Eurasia and Europe. It parallels the RHD pattern (with regard to the specific forms of Rh Neg gene deletion.)
It is hard to “wrap one’s head” around the full technical detail.
Once again they concentrate on the ABO groups and do not mention the rhesus factor ! Despite it being clear in the data the rhesus factor is far more important in determining Covid outcomes than the ABO groups.